Virtual Library

 x 
My Library Virtual Library FAQ

Start Your Search

Y.J. Yuh



Author of

  • +

    P2.03 - Chemotherapy/Targeted Therapy (ID 704)

    • Event: WCLC 2017
    • Type: Poster Session with Presenters Present
    • Track: Chemotherapy/Targeted Therapy
    • Presentations: 1
    • +

      P2.03-022 - Impact of EGFR Mutation on Clinical Outcome of Nintedanib plus Docetaxel in Previously Treated Non- Small Cell Lung Cancer (NSCLC) (ID 8720)

      09:30 - 09:30  |  Author(s): Y.J. Yuh

      • Abstract

      Background:
      Anti-angiogenic agents have been reported to have clinical activity EGFR mutant NSCLC with/without EGFR Tyrosine kinase inhibitor (TKI). We reported clinical outcomes of nintedanib plus docetaxel in refractory NSCLC according to EGFR mutation status during a Korean nintedanib NPU program.

      Method:
      Patients with NSCLC were eligible if they failed at least one prior systemic treatment. Docetaxel was administered either 75mg/m[2] or 37.5mg/m[2] on D1, D8 q every 3weeks plus nintedanib 200mg orally twice daily. Nintedanib treatment was continued until disease progression or unacceptable toxicity after 4-6 cycles of combination therapy.

      Result:
      62 patients were enrolled. 28 patients with activating EGFR mutation (17 in exon19 deletion, 8 exon21 L858R/L861Q, 1 exon 18 G719X, 1 in exon20 duplication, 1 in exon19 deletion and exon20 T790M) progressed after EGFR-TKI, 25/28 patient also progressed after platinum doublet chemotherapy were enrolled. Only for 2 patients EGFR mutation status were unknown. Patients were heavily pretreated, with 38.7% patients receiving nintedanib plus docetaxel as ≥ 4[th] line therapy. 5 patients had received bevacizumab. For patients with response assessment reported objective response rate was 30.6% and median PFS and OS were 3.9 months (95% CI 3.4-4.4) and 11.7months (95% CI 5.2-18.1) respectively in overall patients. Based on EGFR mutation status, objective response rate was 52.1% vs 24.1% (EGFR mut(+) vs EGFR mut (-), p=0.47) and median PFS was 5.9 vs 3.6 months (EGFR mt(+) vs EGFR mt(-), p=0.031). No treatment related death was reported. Common grade 3/4 adverse event were neutropenia (33.8 %), and reversible elevated liver enzyme(9.7%). 10 patients in 150mg twice daily and 2 patients with 100mg twice daily administered grade 3 adverse events. Figure 1



      Conclusion:
      Nintedanib plus docetaxel was well-tolerated and had clinical activity in refractory NSCLC. Specifically, EGFR TKI resistant EGFR mutant NSCLC may be a good candidate for nintedanib plus docetaxel.